Connected Drug Delivery Devices Market

The global market value of the connected drug delivery devices market was valued at USD 5.1 billion in 2024 and is projected to grow at a CAGR of 23.4% during the forecast period. Increasing health and hygiene awareness drives the demand for the connected drug delivery devices market. The increasing prevalence of asthma, COPD, and Diabetes is a major driver. Integration of technologies like Bluetooth and Near Field Communication enables real-time data transmission between devices and healthcare providers. This connectivity allows for better tracking of medication usage and patient adherence.

Rising healthcare expenditures and increasing demand for early diagnosis and treatment are also fueling the market’s growth. Increasing awareness about chronic diseases and their cure is the key factor behind the market’s growth. The pandemic has had a significant impact on this market.

Growth Drivers

The need for continuous patient monitoring has increased the demand for remote healthcare all over the world.  Connected drug delivery devices rapidly increase the speed of the services by providing real-time data, allowing healthcare providers to make timely interventions. Increasing demand for personalized healthcare solutions is fueling the growth in the market significantly. Connected devices contribute to this by collecting data that helps in customizing therapies. The COVID-19 pandemic has had an overall positive impact on the market with increasing awareness of connected devices, adoption by providers & patients, and the importance of remote monitoring for medication adherence.

Growing demand for injectable devices for the better treatment of chronic diseases is spurring the growth in the market. Moreover, the entry of many drug manufacturers to develop smart injectable devices is projected to offer significant growth opportunities for the injectable devices segment during the forecast period.  Increasing investment in healthcare infrastructure by the government is promoting digital health solutions. An increasing number of patients with chronic metabolic disorders, and respiratory diseases in the geriatric population, and ongoing technological advancements are the key drivers in the market.

Segmentation

Product Type Outlook

·         Standalone Components & Software integrated Devices

·         Others

Route of Administration Outlook

·         Parenteral

·         Inhalational

Application Outlook

·         Asthma

·         COPD

·         Diabetes Management

·         Others

 By Region

·         Asia-Pacific

·         North America

·         Latin America

·         Middle East and Africa

·         Europe

Connected Drug Delivery Devices Market by Application

Based on the application, the connected drug delivery market is segmented into asthma, COPD, diabetes management, and others. Asthma is the leading segment in the connected drug delivery market, and COPD is expected to dominate the market during the forecast period. Investment by major pharmaceutical companies like Teva Pharmaceuticals, Propeller Health, and AstraZeneca is developing connected inhaler solutions.

Both asthma and COPD affect hundreds of millions of people globally. This large patient base creates sustained demand for effective and user-friendly drug delivery solutions. Chronic respiratory diseases require long-term and often daily medication, making them ideal candidates for connected devices that monitor adherence and optimize treatment. Inhalers are the primary mode of treatment for both conditions. Poor adherence to inhaled medications is a major issue in asthma and COPD medications.

The diabetes management segment dominated the market in 2023, accounting for over 35% of the total market share. An increasing global population, which is suffering from diabetes, is fueling growth in the market. Integration of Bluetooth technology enables seamless data transmission between devices and healthcare platforms, enhancing remote monitoring and patient engagement. The increasing global population suffering from obesity is significantly contributing to the growth of the market. Rising healthcare expenditure is driving growth in the market. Archived FDA clearance for type 2 diabetes management, marking a significant investment. Increasing growth in the demand for Bluetooth is driving the market significantly. The global market is highly fragmented as a large number of players operate actively here. Adherium, Propeller Health (A ResMed Company), and Cohero Health Inc. are expected to lead the smart inhaler market. Certain factors, such as ownership of technology, emphasis on research & development activities, and robust focus on the consolidation of sales channels are attributable for the companies to hold major connected drug delivery devices market share.

Regional Outlook

On the basis of the regions, the connected drug delivery devices market is analyzed into 5 regions: Asia-Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America is the leading market in the connected drug delivery market and is expected to dominate the market during the forecast period due to rising healthcare expenditure and the presence of global pharmaceutical companies.

An increasing collaboration between healthcare providers and technology companies is driving growth in the market significantly. Increasing awareness among the people to detect and treat diseases effectively is spurring the market growth significantly. Asia Pacific is expected to lead during the forecast period due to rising healthcare expenditure and rising prevalence of chronic diseases due to increasing population. A rapidly growing population is spurring the growth in chronic disease patients, and diabetes asthma, and cardiovascular diseases necessitate advanced drug delivery solutions.

The widespread use of smartphones and wearable devices facilitates the integration of connected drug delivery systems, enhancing patient adherence and real-time monitoring. Aptar Digital Health and SHL Medical collaborated (June 2024) to integrate digital platforms with injectable devices. Increasing demand for enhancing data integrity and accuracy. Increasing demand for Bluetooth devices is driving growth in the market significantly. The presence of key market manufacturers is driving growth significantly in the market.

Supportive policies and investments in digital health infrastructure are promoting the adoption of connected healthcare technology. Features like dose reminders and educational content empower patients to manage their treatment effectively. Europe’s connected drug delivery devices market is also witnessing a rising curve due to an increasing aging population and high demand for efficient and user-friendly drug delivery systems. The need for effective management of chronic conditions is propelling the adoption of connected devices.

Integration of digital technologies in healthcare is enhancing patient monitoring and treatment personalization. The Middle East Africa and Latin America are witnessing significant growth in the market. Countries like Brazil, Argentina, Mexico, Israel, Saudi Arabia, and the United Arab Emirates are witnessing significant growth due to rising healthcare expenditures and the rising prevalence of chronic diseases all over the world.

Key Players

·         Teva Respiratory, LLC

·         Novo Nordisk A/S

·         Phillips-Medisize, LLC

·         Medtronic

·         Adherium Limited

·         Tandem Diabetes Care, Inc.

·         Biocorp

·         Propeller health

·         Ypsomed AG

·         Aptar Pharma

·         Other Players